High-Density Lipoproteins and the Kidney
Open Access
Abstract
Dyslipidemia is a typical trait of patients with chronic kidney disease (CKD) and it is typically characterized by reduced high-density lipoprotein (HDL)-cholesterol(c) levels. The low HDL-c concentration is the only lipid alteration associated with the progression of renal disease in mild-to-moderate CKD patients. Plasma HDL levels are not only reduced but also characterized by alterations in composition and structure, which are responsible for the loss of atheroprotective functions, like the ability to promote cholesterol efflux from peripheral cells and antioxidant and anti-inflammatory proprieties. The interconnection between HDL and renal function is confirmed by the fact that genetic HDL defects can lead to kidney disease; in fact, mutations in apoA-I, apoE, apoL, and lecithin–cholesterol acyltransferase (LCAT) are associated with the development of renal damage. Genetic LCAT deficiency is the most emblematic case and represents a unique tool to evaluate the impact of alterations in the HDL system on the progression of renal disease. Lipid abnormalities detected in LCAT-deficient carriers mirror the ones observed in CKD patients, which indeed present an acquired LCAT deficiency. In this context, circulating LCAT levels predict CKD progression in individuals at early stages of renal dysfunction and in the general population. This review summarizes the main alterations of HDL in CKD, focusing on the latest update of acquired and genetic LCAT defects associated with the progression of renal disease.Keywords
This publication has 96 references indexed in Scilit:
- Serum Amyloid A in Uremic HDL Promotes InflammationJournal of the American Society of Nephrology, 2012
- APOL1 Genetic Variants in Focal Segmental Glomerulosclerosis and HIV-Associated NephropathyJournal of the American Society of Nephrology, 2011
- Uremia Alters HDL Composition and FunctionJournal of the American Society of Nephrology, 2011
- Plasma apolipoprotein C-III metabolism in patients with chronic kidney diseaseJournal of Lipid Research, 2011
- Cholesterol Efflux Capacity, High-Density Lipoprotein Function, and AtherosclerosisNew England Journal of Medicine, 2011
- Association of Trypanolytic ApoL1 Variants with Kidney Disease in African AmericansScience, 2010
- Functional Lecithin: Cholesterol Acyltransferase Is Not Required for Efficient Atheroprotection in HumansCirculation, 2009
- Lipid and Lipoprotein Metabolism in Chronic Kidney DiseaseJournal of Renal Nutrition, 2009
- Apolipoprotein L1, a Novel Bcl-2 Homology Domain 3-only Lipid-binding Protein, Induces Autophagic Cell DeathJournal of Biological Chemistry, 2008
- Emerging Biomarkers for Evaluating Cardiovascular Risk in the Chronic Kidney Disease PatientClinical Journal of the American Society of Nephrology, 2008